X4 Pharmaceuticals

X4 Pharmaceuticals

Biotechnology Research

Boston, Massachusetts 11,190 followers

Enabling a better future for people with rare immune disorders

About us

We are a commercial-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system and few to no treatment options. We have successfully developed mavorixafor, receiving FDA approval for XOLREMDI™ (mavorixafor) in its first indication, and are currently executing our US launch. We are also advancing mavorixafor for additional rare disease patient populations, and expect to initiate a pivotal, global Phase 3 clinical trial in people with certain chronic neutropenic disorders. With a focus on CXCR4 and immune system biology, we continue to leverage our expertise both at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria to further advance our patient-centric mission.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Boston, Massachusetts
Type
Public Company
Founded
2014
Specialties
Rare disease and primary immunodeficiencies

Locations

Employees at X4 Pharmaceuticals

Updates

Similar pages

Browse jobs

Funding

X4 Pharmaceuticals 11 total rounds

Last Round

Post IPO debt

US$ 115.0M

See more info on crunchbase